## Core Concept
Tumor lysis syndrome (TLS) is a life-threatening complication that occurs when a large number of cancer cells die rapidly, releasing their contents into the bloodstream. This leads to hyperuricemia, hyperphosphatemia, hypocalcemia, and hyperkalemia. TLS is commonly associated with hematological malignancies, such as acute lymphoblastic leukemia (ALL) and Burkitt lymphoma.

## Why the Correct Answer is Right
The correct answer, , implies that one of the statements provided is not true regarding tumor lysis syndrome. To assess this, we need to evaluate each option based on known facts about TLS.

## Why Each Wrong Option is Incorrect
- **Option A:** Typically, TLS is characterized by hyperuricemia due to the breakdown of nucleic acids from lysed cancer cells into uric acid. Therefore, any statement contradicting this or other established features of TLS would be incorrect.
- **Option B:** Hyperphosphatemia is a hallmark of TLS, resulting from the release of phosphate from lysed cells. This often leads to secondary hypocalcemia due to calcium phosphate precipitation.
- **Option C:** Hyperkalemia is another critical feature, caused by the release of potassium from dying cells, which can lead to cardiac arrhythmias.
- **Option D:** Without specific details on each option, we must infer based on common knowledge about TLS. Typically, TLS does not present with hypouricemia; instead, hyperuricemia is a key feature.

## Clinical Pearl / High-Yield Fact
A crucial point to remember is that TLS can be prevented or managed with aggressive hydration, urinary alkalinization (to increase uric acid solubility), and the use of allopurinol (a xanthine oxidase inhibitor) or rasburicase (an urate oxidase) to control hyperuricemia.

## Correct Answer: D. Hypouricemia